Product Description
3D011 is an in-house discovered tyrosine kinase inhibitor (TKI) prodrug that will be developed as monotherapy and in combination with other agents for the treatment of solid tumors. We received IND approval from the NMPA in January 2021, and we initiated this Phase I clinical trial in February 2022. On June 7, 2022, a U.S. patent for 3D011 was granted by the United States Patent and Trademark Office. On December 28, 2022, a European patent for 3D011 was granted by European Patent Office. As of the date of this report, we are conducting an open-label, single-arm Phase I dose-escalation and dose-expansion clinical trial in patients with advanced solid tumors. (Sourced from: https://en.3d-medicines.com/pipeline/81.html)
Mechanisms of Action: TK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: 3D Medicines (Beijing) Co., Ltd.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified|Renal Cell Carcinoma|Prostate Cancer|Hepatocellular Carcinoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05099536 |
3D011-CN-001 | P1 |
Withdrawn |
Oncology Solid Tumor Unspecified |
2023-09-11 |
2024-02-01 |
||
CTR20212756 |
CTR20212756 | P1 |
Not yet recruiting |
Renal Cell Carcinoma|Prostate Cancer|Hepatocellular Carcinoma |
None |
2025-04-29 |
Patient Enrollment|Treatments |
Recent News Events
Date |
Type |
Title |
|---|